For the Inventor, By the Inventor

Enter inventor name

La Jolla, CA, United States of America

Andrew A Young

USPTO Granted Patents = 68 (Patent Applications = 18)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 2.8

ph-index = 30

Forward Citations = 2,214(Granted Patents)

Forward Citations (Not Self Cited) = 2,027(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Alpine, CA (US) (1998 - 2008)
Rancho Sante Fe, CA (US) (2010)
La Jolla, CA (US) (2005 - 2012)
Rancho Santa Fe, CA (US) (2006 - 2013)
San Diego, CA (US) (1993 - 2015)
Chapel Hill, NC (US) (2012 - 2022)
Research Triangle Park, NC (US) (2012 - 2023)
Boston, MA (US) (2020 - 2023)

Company Filing History:

Amylin Pharmaceuticals, Inc.

Satiogen Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Intarcia Therapeutics, Inc.

I2o Therapeutics, Inc.

6. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1993-2023

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Glucagon-Receptor Selective Polypeptides

Bile Acid Recycling Inhibitors

Exendin Agonists

GIP Analog Polypeptides

Amylin Agonists

Diabetes Treatment

Obesity Management

Peptide Therapeutics

Gastrointestinal Disorders

Endocrine Peptide Regulation

Satiogens

Metabolic Diseases

68 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11840559 - Glucagon-receptor selective polypeptides and methods of use thereof (2023-12-12),

2. 11654183 - Methods comprising continuous administration of exenatide and co-administration of a drug (2023-05-23),

3. 11260053 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions (2022-03-01),

4. 11214607 - Glucagon-receptor selective polypeptides and methods of use thereof (2022-01-04),

5. 10835580 - Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug (2020-11-17),

6. 10555950 - Bile acid recycling inhibitors for treatment of obesity and diabetes (2020-02-11),

7. 10501517 - Glucagon-receptor selective polypeptides and methods of use thereof (2019-12-10),

8. 10251880 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions (2019-04-09),

9. 10188646 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions (2019-01-29),

10. 10028952 - Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof (2018-07-24),

11. 9345715 - Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof (2016-05-24),

12. 9339480 - Bile acid recycling inhibitors for treatment of obesity and diabetes (2016-05-17),

13. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

14. 8951962 - Modified exendins and exendin agonists (2015-02-10),

15. 8895498 - GIP and exendin hybrid polypeptides (2014-11-25),

Title: The Innovative Journey of Andrew A. Young

Introduction: Andrew A. Young, a distinguished inventor based in La Jolla, CA, has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Andrew A. Young holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights: Throughout his illustrious career, Andrew A. Young has worked with leading tech companies to develop cutting-edge solutions that have revolutionized industries. His passion for innovation and problem-solving has led to the creation of products that have improved the lives of many.

Collaborations: Andrew A. Young has collaborated with top researchers, engineers, and scientists from around the world to bring his ideas to life. His ability to work in multidisciplinary teams has resulted in successful projects that have pushed the boundaries of technology.

Conclusion: In conclusion, Andrew A. Young's relentless pursuit of innovation and his commitment to excellence have established him as a prominent figure in the world of inventors. His remarkable contributions continue to inspire future generations of innovators to think outside the box and create solutions that shape the world we live in.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…